David A. Siegel Biotechnology

Two Sigma Advisers, LP

$42.8 Billion
Q1 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
CABA Cabaletta Bio, Inc.	$63.3M	$655,000 0.0% of portfolio	471,500	Q1 2025 Reduced 43.32%
RYTM Rhythm Pharmaceuticals, Inc.	$3.66B	$640,000 0.0% of portfolio	12,100	Q1 2025 Reduced 7.63%
YMAB Y M Abs Therapeutics, Inc.	$223M	$634,000 0.0% of portfolio	143,300	Q1 2025 Added 93.91%
NUVB Nuvation Bio Inc.	$539M	$631,000 0.0% of portfolio	358,800	Q1 2025 Reduced 24.69%
FATE Fate Therapeutics Inc	$147M	$621,000 0.0% of portfolio	787,000	Q1 2025 Reduced 4.96%
ANTX An2 Therapeutics, Inc.	$21.3M	$605,000 0.0% of portfolio	445,004	Q1 2025 Reduced 15.77%
SGMO Sangamo Therapeutics, Inc	$76.7M	$593,000 0.0% of portfolio	899,255	Q1 2025 Added 27.09%
DSGN Design Therapeutics, Inc.	$223M	$566,000 0.0% of portfolio	146,700	Q1 2025 Reduced 37.28%
PMVP Pmv Pharmaceuticals, Inc.	$43.3M	$551,000 0.0% of portfolio	505,600	Q1 2025 Reduced 29.25%
OCUL Ocular Therapeutix, Inc	$664M	$535,000 0.0% of portfolio	73,100	Q1 2025 Added 99.18%
OLMA Olema Pharmaceuticals, Inc.	$179M	$518,000 0.0% of portfolio	138,000	Q1 2025 Added 55.06%
ABOS Acumen Pharmaceuticals, Inc.	$44.1M	$510,000 0.0% of portfolio	463,700	Q1 2025 Reduced 7.09%
RXRX Recursion Pharmaceuticals, Inc.	$825M	$504,000 0.0% of portfolio	95,445	Q1 2025 Reduced 78.87%
ALEC Alector, Inc.	$116M	$483,000 0.0% of portfolio	392,900	Q1 2025 Reduced 8.61%
DNLI Denali Therapeutics Inc.	$1.96B	$480,000 0.0% of portfolio	35,300	Q1 2025 Added 133.77%
ACET Adicet Bio, Inc.	$30M	$473,000 0.0% of portfolio	622,839	Q1 2025 Reduced 21.56%
ERAS Erasca, Inc.	$192M	$470,000 0.0% of portfolio	343,100	Q1 2025 Reduced 42.3%
ELYM Eliem Therapeutics, Inc.	$109M	$468,000 0.0% of portfolio	114,000	Q1 2025 Added 2.06%
TYRA Tyra Biosciences, Inc.	$445M	$465,000 0.0% of portfolio	50,100	Q1 2025 Added 307.32%
PLRX Pliant Therapeutics, Inc.	$79.8M	$461,000 0.0% of portfolio	342,200	Q1 2025 Added 152.17%
ORMP Oramed Pharmaceuticals Inc.	$84.6M	$455,000 0.0% of portfolio	213,000	Q1 2025 Reduced 11.76%
EPIX Essa Pharma Inc.	$75.4M	$436,000 0.0% of portfolio	276,100	Q1 2025 Added 234.26%
ALXO Alx Oncology Holdings Inc	$22M	$422,000 0.0% of portfolio	681,000	Q1 2025 Reduced 17.34%
RAPT Rapt Therapeutics, Inc.	$30.2M	$397,000 0.0% of portfolio	325,900	Q1 2025 Reduced 35.3%
APLT Applied Therapeutics Inc.	$17.3M	$322,000 0.0% of portfolio	658,400	Q1 2025 New
TERN Terns Pharmaceuticals, Inc.	$134M	$302,000 0.0% of portfolio	109,600	Q1 2025 New
IMAB I Mab	$190M	$297,000 0.0% of portfolio	363,200	Q1 2025 Reduced 15.69%
CDXS Codexis, Inc.	$148M	$267,000 0.0% of portfolio	99,500	Q1 2025 Reduced 75.35%
AUTL Autolus Therapeutics PLC	$218M	$255,000 0.0% of portfolio	164,700	Q1 2025 Reduced 50.6%
AKBA Akebia Therapeutics, Inc.	$632M	$249,000 0.0% of portfolio	129,749	Q1 2025 Reduced 9.36%
WVE Wave Life Sciences Ltd.	$606M	$239,000 0.0% of portfolio	29,600	Q1 2025 Reduced 56.53%
VTYX Ventyx Biosciences, Inc.	$127M	$226,000 0.0% of portfolio	196,529	Q1 2025 Reduced 75.46%
CELC Celcuity Inc.	$196M	$221,000 0.0% of portfolio	21,900	Q1 2025 Reduced 57.23%
NKTX Nkarta, Inc.	$89M	$221,000 0.0% of portfolio	120,300	Q1 2025 Added 16.23%
TBPH Theravance Biopharma, Inc.	$719M	$220,000 0.0% of portfolio	24,700	Q1 2025 New
CRNX Crinetics Pharmaceuticals, Inc.	$1.78B	$211,000 0.0% of portfolio	6,300	Q1 2025 Reduced 22.22%
LYEL Lyell Immunopharma, Inc.	$2.84B	$211,000 0.0% of portfolio	391,200	Q1 2025 Added 27.68%
FGEN Fibrogen Inc	$29.1M	$209,000 0.0% of portfolio	676,206	Q1 2025 Reduced 23.02%
PRLD Prelude Therapeutics Inc	$36.4M	$200,000 0.0% of portfolio	260,400	Q1 2025 Reduced 13.2%
IKNA Ikena Oncology, Inc.	$50.8M	$193,000 0.0% of portfolio	151,400	Q1 2025 Reduced 3.81%
REPL Replimune Group, Inc.	$481M	$191,000 0.0% of portfolio	19,600	Q1 2025 Reduced 88.5%
ALDX Aldeyra Therapeutics, Inc.	$150M	$190,000 0.0% of portfolio	33,100	Q1 2025 Reduced 73.58%
CGEM Cullinan Oncology, Inc.	$399M	$190,000 0.0% of portfolio	25,100	Q1 2025 Added 14.61%
ETNB 89bio, Inc.	$473M	$180,000 0.0% of portfolio	24,800	Q1 2025 Reduced 77.88%
EYPT Eye Point Pharmaceuticals, Inc.	$290M	$163,000 0.0% of portfolio	30,100	Q1 2025 Reduced 71.2%
STRO Sutro Biopharma, Inc.	$44.3M	$156,000 0.0% of portfolio	240,900	Q1 2025 Reduced 56.02%
CGEN Compugen LTD	$152M	$155,000 0.0% of portfolio	106,184	Q1 2025 Added 196.74%
ARVN Arvinas, Inc.	$417M	$153,000 0.0% of portfolio	21,900	Q1 2025 Reduced 92.25%
HLVX Hille Vax, Inc.	$65.5M	$148,000 0.0% of portfolio	102,376	Q1 2025 Added 148.49%
ANVS Annovis Bio, Inc.	$21.1M	$139,000 0.0% of portfolio	92,921	Q1 2025 New

Shares Options

David A. Siegel

David A. Siegel is the co-founder and CEO of Two Sigma Advisers, a successful investment firm that uses technology and data-driven approaches to investing. Siegel is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.

Track David A. Siegel's portfolio

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account